Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 11;105(1):148–160. doi: 10.3324/haematol.2018.208835

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 4. — Knockdown of TET1 expression recapitulates effects of homoharringtonine (HHT) treatment in acute myeloid leukemia (AML) cells. (A) Qualitative polymerase chain reaction (qPCR) analysis of TET1 knockdown efficacy in MONOMAC 6, MA9.3ITD and MA9.3RAS cells. (B) Effects of TET1 knockdown on cell growth/proliferation of these three AML cell lines at different time points [0, 24, 48, 72 and 96 hours (h)]. (C) Effects of TET1 knockdown on apoptosis in MA9.3ITD and MA9.3RAS AML cells. (D) Statistical analysis of apoptosis assay in AML cells from three independent experiments determined by flow cytometry. (E) Effects of TET1 knockdown on cell cycle arrest in AML cells. (F) Statistical analysis of cell cycle assays from three independent experiments determined by flow cytometry. (G) Statistical analysis of cell proportions of CD11b⁺CD14⁺ and CD11b⁻CD14⁻ in TET1 knockdown or control MONOMAC 6 cells. (H) HHT IC₅₀ in MA9.3ITD and MA9.3RAS cells with or without TET1 knockdown. These cells were exposed to HHT for 72 h. *P<0.05; **P<0.01; ***P<0.001; t-test. Error bar, mean±Standard Deviation.